Recent policies to reduce drug costs and the budget deficit in Croatia: impact and example to others

Content Provider	Semantic Scholar
Copyright Year	2011
Abstract	Contact details: 4app. Stepanyan 13, Nor Nork second block, Yerevan 0065, Republic of Armenia, tel:+37494811523 e-mail:anush.peri@gmail.com Conference strand in which the abstract is submitted (for selection): Strand 2 – Rational use of medicines Title of the abstract: Essential Medicines in Private Pharmaceutical Market of Armenia First author: Perikhanyan A.V. MS, MPH Yerevan State Medical University, Department of Pharmaceutical Management Associated Authors: Hakobyan A. A. MD, PhD, Beglaryan M.H. MD, PhD Yerevan State Medical University, Department of Pharmaceutical Management Problem Statement: In many developing countries the necessary essential medicines are not always available, accessible, and affordable to those in need. The aim of the national pharmaceutical policy is to supply a country with efficient, safe and high quality drugs that would be equally accessible for each citizen. Objective(s): Based on the internationally accepted concept by World Health Organization (WHO) that the essential drugs are intended to be available within the context of functioning health systems at all times in adequate amounts, in the appropriate dosage forms, with assured quality and adequate information, and at a price the community can afford, we aimed to observe the pharmaceutical market of Armenia with regard to availability of essential drugs, to price difference among generics with the same active ingredient and to some other representative parameters of supplied and produced drugs in Armenia. Policy/ies targeted: generic promotion ,essential medicines Stakeholder(s) involved: Region covered: WHO region, national level Study design: Analysis Time period: From February 2011 to May 2011 Setting: Private sector Intervention(s): Information about essential medicines was elicited from price-lists of four largest vendor companies in December 2010. Provision of essential pharmaceuticals was described, compared and analyzed based on information about drug names (range). Result(s): According to our analysis Armenian biggest wholesalers receive and distribute essential medicines from 42 foreign exporters. Germany and Ukraine share the first place by product delivery (8.2%). The local production of drugs is comprised 13.4%, all generics. The most importable drugs from the list of essentials were “Diclofenac” and “Ceftriaxone”. The widest range of essential drugs by therapeutic group was a group of anti-infective drugs for systematic use (28.2%). Generics were more (76.8%) than known brands (21.8%). All companies together delivered 168 (54.4%) drug names from 309 in the National List of Essential Medicines (NLEM). Hundred thirty two drug names (14.1%) in required dosages by NLEM were not found among 936 drugs suggested by companies. By assuming that the price difference between the most expensive generic and the cheapest generic should not vary significantly we received one extreme difference with “Aciclovir 200mg No 20 tablets package” was approximately $23. The mean price difference of other generics was approximately 1.500 AMD (Armenian Drams) or $ 4.1 (SD-1816.6, Mean-1496.6, 95%CI [6212372]). Only the prices of wide range of medications were compared. Balancing pharmaceutical policies between equity and cost-containment – PPRI Conference 2011 29/30 September 2011, Vienna 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 N = NAME Tolol5 Rxitrom Mtronid Latadi Fconaz Elapri Dlofen Dameth Croflo Cftriax Cfazoli Cabamaz Anolol Apirin1 Alodipi Aitript Aiadaro Aendaz Aiclovi Th e di ffe re nc e of g en er ik -g en er ik 10000
File Format	PDF HTM / HTML
Alternate Webpage(s)	https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/Abstract_poster_book.pdf
Language	English
Access Restriction	Open
Content Type	Text
Resource Type	Article